Feed DVA
DV

DaVita

DVA · NYSE

$181.48 +0.08% (+$0.15)
1M +1.33%
Market Cap $11.6B
P/E Ratio 13.74x
Div. Yield -
ROE -

Bulios Fair Price

$230.59

27.1% upside

Current Price

$181.48

Undervalued Fair Value Overvalued

According to Bulios Fair Price, DVA is currently undervalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
95 /100
Cheap
P/E 13.74x
EV/EBITDA 7.88x
P/S 0.83x
Growth
66 /100
Stable
EPS growth 18.54%
Rev. growth 5.53%
FCF growth 10.89%
Profitability
61 /100
Moderate
Gross margin 31.02%
Net margin 6.05%
Op. margin 15.06%
Quality
59 /100
Average
ROIC 11.18%
ROA 4.79%
Asset turnover 0.79x
Debt
44 /100
Moderate
Current ratio 1.47x
Int. coverage 3.67x
Net debt/EBITDA 3.66x
Stability
90 /100
Stable
Beta 0.87x
Rev. volatility 0.95%
EPS volatility 29.03%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about DVA
Online

About the company

DaVita Inc. is an American company specializing in providing dialysis services and managing nephrology centers. The company is headquartered in Denver, Colorado, and is one of the leading providers of dialysis care in the United States and other countries. Its services include dialysis in hospitals, independent dialysis centers, and home dialysis.

Sector

Healthcare

Industry

Medical - Care Facilities

CEO

Javier J. Rodriguez

Employees

78,000

Headquarters

Denver

Upcoming events

28 OCT

Earnings

Upcoming earnings report

46d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.